The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Living Donors

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Living Donors

 

High impact information on Living Donors

 

Chemical compound and disease context of Living Donors

 

Biological context of Living Donors

 

Anatomical context of Living Donors

 

Associations of Living Donors with chemical compounds

  • Among patients receiving cyclosporine, the maintenance 12-month dose in living donor graft recipients increased from 6.4 mg/kg per day for patients who had transplants done in 1987 to 7.9 mg/kg per day for patients who had transplants done in 1992 (P = 0.02) [10].
  • Our experience over the last 4 years with HLA-identical, donor-specific transfusion (DST), and Imuran (IM) + DST living-donor transplants in 206 patients is presented [23].
  • Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations [24].
  • BACKGROUND: In a living-donor liver transplant patient continuously receiving tacrolimus (FK506), pulse steroid therapy for 3 days caused the blood concentration of FK506 to decrease, followed by a gradual recovery to presteroid levels within 2 weeks [25].
  • Of the 44 patients who entered the DST or IM + DST protocols but were not transplanted, 31 patients (70%) have subsequently been transplanted, and all 5 recipients of living-donor kidneys and 20 of 26 recipients of cadaveric kidneys (77%) have functioning grafts [23].
 

Gene context of Living Donors

 

Analytical, diagnostic and therapeutic context of Living Donors

References

  1. Effect of intravascular volume expansion on renal function during prolonged CO2 pneumoperitoneum. London, E.T., Ho, H.S., Neuhaus, A.M., Wolfe, B.M., Rudich, S.M., Perez, R.V. Ann. Surg. (2000) [Pubmed]
  2. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Cheng, S.J., Pratt, D.S., Freeman, R.B., Kaplan, M.M., Wong, J.B. Transplantation (2001) [Pubmed]
  3. Temporary auxiliary liver transplantation from living donor to an adult recipient with familial amyloid polyneuropathy. Ikegami, T., Nishizaki, T., Shimada, M. Transplantation (2002) [Pubmed]
  4. Living donor liver transplant for malignancy. Axelrod, D., Koffron, A., Kulik, L., Al-Saden, P., Mulcahy, M., Baker, T., Fryer, J., Abecassis, M. Transplantation (2005) [Pubmed]
  5. Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Araki, M., Fahmy, N., Zhou, L., Kumon, H., Krishnamurthi, V., Goldfarb, D., Modlin, C., Flechner, S., Novick, A.C., Fairchild, R.L. Transplantation (2006) [Pubmed]
  6. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Gondolesi, G.E., Roayaie, S., Muñoz, L., Kim-Schluger, L., Schiano, T., Fishbein, T.M., Emre, S., Miller, C.M., Schwartz, M.E. Ann. Surg. (2004) [Pubmed]
  7. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Matas, A.J., Kandaswamy, R., Humar, A., Payne, W.D., Dunn, D.L., Najarian, J.S., Gruessner, R.W., Gillingham, K.J., McHugh, L.E., Sutherland, D.E. Ann. Surg. (2004) [Pubmed]
  8. Differential expression of heme oxygenase-1 and vascular endothelial growth factor in cadaveric and living donor kidneys after ischemia-reperfusion. Lemos, F.B., Ijzermans, J.N., Zondervan, P.E., Peeters, A.M., van den Engel, S., Mol, W.M., Weimar, W., Baan, C.C. J. Am. Soc. Nephrol. (2003) [Pubmed]
  9. Lessons learned from more than 1,000 pancreas transplants at a single institution. Sutherland, D.E., Gruessner, R.W., Dunn, D.L., Matas, A.J., Humar, A., Kandaswamy, R., Mauer, S.M., Kennedy, W.R., Goetz, F.C., Robertson, R.P., Gruessner, A.C., Najarian, J.S. Ann. Surg. (2001) [Pubmed]
  10. Higher maintenance cyclosporine dose decreases the risk of graft failure in North American children: a report of the North American Pediatric Renal Transplant Cooperative Study. Tejani, A., Sullivan, E.K. J. Am. Soc. Nephrol. (1996) [Pubmed]
  11. Major influence of liver function itself but not of immunosuppression determines glucose tolerance after living-donor liver transplantation. Stockmann, M., Konrad, T., Nolting, S., Hünerbein, D., Wernecke, K.D., Döbling, H., Steinmüller, T., Neuhaus, P. Liver Transpl. (2006) [Pubmed]
  12. Factors determining the prevalence of hypertension after renal transplantation. Huysmans, F.T., Hoitsma, A.J., Koene, R.A. Nephrol. Dial. Transplant. (1987) [Pubmed]
  13. Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Kishi, Y., Sugawara, Y., Akamatsu, N., Kaneko, J., Tamura, S., Kokudo, N., Makuuchi, M. Clinical transplantation. (2005) [Pubmed]
  14. Is kidney graft biopsy indicated in recipients with newly developed, microscopic hematuria? Kim, Y.S., Jeong, H.J., Kim, M.S., Kim, S.I., Han, D.S., Park, K. Clinical transplantation. (1998) [Pubmed]
  15. Successful treatment of sepsis with polymyxin b-immobilized fiber hemoperfusion in a child after living donor liver transplantation. Morishita, Y., Kita, Y., Ohtake, K., Kusano, E., Hishikawa, S., Mizuta, K., Kawarasaki, H. Dig. Dis. Sci. (2005) [Pubmed]
  16. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Okuda, M., Tanaka, K., Inui, K. Pharmacogenetics (2004) [Pubmed]
  17. Suppressed erythropoiesis after ABO-minor-mismatched living-donor lobar lung transplantation. Ogo, H., Ikeda, K., Asano, N., Sano, Y., Date, H., Koide, N., Shimizu, N., Harada, M. J. Heart Lung Transplant. (2004) [Pubmed]
  18. Glomerular hyperfiltration after unilateral nephrectomy in living kidney donors. Bock, H.A., Bachofen, M., Landmann, J., Thiel, G. Transpl. Int. (1992) [Pubmed]
  19. Look-up survival tables for living-donor renal transplants: OPTN/UNOS data 1995-2002. Gjertson, D.W. Clinical transplants. (2003) [Pubmed]
  20. IP-10, apoptotic genes, and calcineurin subtype messenger RNA kinetics occurring in rat renal isografts from brain-dead donors. Kusaka, M., Fukami, N., Sasaki, H., Higuchi, T., Ishikawa, K., Shiroki, R., Hoshinaga, K. Transplant. Proc. (2005) [Pubmed]
  21. Impact of graft hepatic vein inferior vena cava reconstruction with graft venoplasty and inferior vena cava cavoplasty in living donor adult liver transplantation using a left lobe graft. Suehiro, T., Shimada, M., Kishikawa, K., Shimura, T., Soejima, Y., Yoshizumi, T., Hashimoto, K., Mochida, Y., Maehara, Y., Kuwano, H. Transplantation (2005) [Pubmed]
  22. Using a radial artery as an interpositional vascular graft in a living-donor liver transplantation for hepatocellular carcinoma. Mizuno, S., Yokoi, H., Isaji, S., Yamagiwa, K., Tabata, M., Shimono, T., Miya, F., Takada, Y., Uemoto, S. Transpl. Int. (2005) [Pubmed]
  23. A four-year experience with donor blood transfusion protocols for living-donor renal transplantation. Glass, N.R., Miller, D.T., Sollinger, H.W., Belzer, F.O. Transplantation (1985) [Pubmed]
  24. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Kim, Y.S., Moon, J.I., Kim, S.I., Park, K. Transplantation (1999) [Pubmed]
  25. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Shimada, T., Terada, A., Yokogawa, K., Kaneko, H., Nomura, M., Kaji, K., Kaneko, S., Kobayashi, K., Miyamoto, K. Transplantation (2002) [Pubmed]
  26. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Härtel, C., Schumacher, N., Fricke, L., Ebel, B., Kirchner, H., Müller-Steinhardt, M. Clin. Chem. (2004) [Pubmed]
  27. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Masuda, S., Uemoto, S., Hashida, T., Inomata, Y., Tanaka, K., Inui, K. Clin. Pharmacol. Ther. (2000) [Pubmed]
  28. Effect of brain death on gene expression and tissue activation in human donor kidneys. Nijboer, W.N., Schuurs, T.A., van der Hoeven, J.A., Fekken, S., Wiersema-Buist, J., Leuvenink, H.G., Hofker, S., Homan van der Heide, J.J., van Son, W.J., Ploeg, R.J. Transplantation (2004) [Pubmed]
  29. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: Observations in 3 cases. Ko, S., Okano, E., Kanehiro, H., Matsumoto, M., Ishizashi, H., Uemura, M., Fujimura, Y., Tanaka, K., Nakajima, Y. Liver Transpl. (2006) [Pubmed]
  30. Expression of MHC Class I-Related Chain B (MICB) Molecules on Renal Transplant Biopsies. Quiroga, I., Salio, M., Koo, D.D., Cerundolo, L., Shepherd, D., Cerundolo, V., Fuggle, S.V. Transplantation (2006) [Pubmed]
  31. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Masuda, S., Goto, M., Fukatsu, S., Uesugi, M., Ogura, Y., Oike, F., Kiuchi, T., Takada, Y., Tanaka, K., Inui, K. Clin. Pharmacol. Ther. (2006) [Pubmed]
  32. Successful long-term outcome with 0-haplotype-matched living-related kidney donors. Jones, J.W., Gillingham, K.J., Sutherland, D.E., Payne, W.D., Dunn, D.L., Gores, P.F., Gruessner, R.W., Najarian, J.S., Matas, A.J. Transplantation (1994) [Pubmed]
  33. Donor-specific transfusions have long-term beneficial effects for human renal allografts. Flye, M.W., Burton, K., Mohanakumar, T., Brennan, D., Keller, C., Goss, J.A., Sicard, G.A., Anderson, C.B. Transplantation (1995) [Pubmed]
  34. Living kidney donors and hypoxia-inducible factor-1alpha. Baan, C., van Gelder, T., Peeters, A., Mol, W., Niesters, H., Weimar, W., IJzermans, J. Transplantation (2003) [Pubmed]
  35. Renal transplantation from HLA-haploidentical living donors. Efficacy of cyclosporine in a multicenter study. Albrechtsen, D., Flatmark, A., Lundgren, G., Brynger, H., Frödin, L., Groth, C., Gäbel, H., Thorsby, E. Transplant. Proc. (1987) [Pubmed]
 
WikiGenes - Universities